{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T06:31:45Z","timestamp":1794983505166,"version":"4.9.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009401","name":"LMU Munich Faculty of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006186","name":"Deutsche Gesellschaft f\u00fcr Urologie eV","doi-asserted-by":"publisher","award":["TaA1\/FE-21"],"award-info":[{"award-number":["TaA1\/FE-21"]}],"id":[{"id":"10.13039\/501100006186","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HE 5825\/9-1"],"award-info":[{"award-number":["HE 5825\/9-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.biopha.2024.117066","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T03:04:48Z","timestamp":1720407888000},"page":"117066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Immunomodulatory imide drugs inhibit human detrusor smooth muscle contraction and growth of human detrusor smooth muscle cells, and exhibit vaso-regulatory functions"],"prefix":"10.1016","volume":"177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4659-2262","authenticated-orcid":false,"given":"Alexander","family":"Tamalunas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Wendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Springer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Vigodski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Trieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Eitelberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Poth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ciotkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Rutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7313-2088","authenticated-orcid":false,"given":"Stephan","family":"Ledderose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Rogenhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kolben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elfriede","family":"N\u00f6ssner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hennenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.117066_bib1","article-title":"Management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. Benign prostatic obstruction (BPO). EAU Guidelines. Edn. presented at","author":"Cornu","year":"2023","journal-title":"EAU Annu. Congr. Milan."},{"key":"10.1016\/j.biopha.2024.117066_bib2","first-page":"1","article-title":"Overview on the lower urinary tract","volume":"202","author":"Chapple","year":"2011","journal-title":"Handb. Exp. Pharm."},{"issue":"Suppl 9","key":"10.1016\/j.biopha.2024.117066_bib3","first-page":"S3","article-title":"Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia","volume":"6","author":"Lepor","year":"2004","journal-title":"Rev. Urol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117066_bib4","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1152\/physrev.00038.2003","article-title":"Urinary bladder contraction and relaxation: physiology and pathophysiology","volume":"84","author":"Andersson","year":"2004","journal-title":"Physiol. Rev."},{"issue":"7","key":"10.1016\/j.biopha.2024.117066_bib5","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","article-title":"Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction","volume":"108","author":"Irwin","year":"2011","journal-title":"BJU Int."},{"issue":"7","key":"10.1016\/j.biopha.2024.117066_bib6","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1464-410X.2005.05454.x","article-title":"A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder","volume":"95","author":"Chapple","year":"2005","journal-title":"BJU Int."},{"issue":"5","key":"10.1016\/j.biopha.2024.117066_bib7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1742-1241.2010.02626.x","article-title":"Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature","volume":"65","author":"Sexton","year":"2011","journal-title":"Int J. Clin. Pr."},{"issue":"9","key":"10.1016\/j.biopha.2024.117066_bib8","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1742-1241.2010.02449.x","article-title":"Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder","volume":"64","author":"Wagg","year":"2010","journal-title":"Int J. Clin. Pr."},{"issue":"6","key":"10.1016\/j.biopha.2024.117066_bib9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/bju.12773","article-title":"Mirabegron the first beta3-adrenoceptor agonist for overactive bladder (OAB): a summary of the phase III studies","volume":"113","author":"Chapple","year":"2014","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.biopha.2024.117066_bib10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.eururo.2011.03.054","article-title":"The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update","volume":"60","author":"Athanasopoulos","year":"2011","journal-title":"Eur. Urol."},{"key":"10.1016\/j.biopha.2024.117066_bib11","article-title":"Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study","author":"Cindolo","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.biopha.2024.117066_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/pros.24114","article-title":"Inhibition of human prostate stromal cell growth and smooth muscle contraction by thalidomide: A novel remedy in LUTS?","author":"Tamalunas","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.biopha.2024.117066_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119771","article-title":"Lenalidomide and pomalidomide inhibit growth of prostate stromal cells and human prostate smooth muscle contraction","volume":"281","author":"Tamalunas","year":"2021","journal-title":"Life Sci."},{"issue":"5971","key":"10.1016\/j.biopha.2024.117066_bib14","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.biopha.2024.117066_bib15","first-page":"308","article-title":"Lenalidomide (Revlimid): a thalidomide analogue in combination with dexamethasone for the treatment of all patients with multiple myeloma","volume":"41","author":"Cruz","year":"2016","journal-title":"P T"},{"issue":"4","key":"10.1016\/j.biopha.2024.117066_bib16","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2174\/156800912800190893","article-title":"Clinical experience with thalidomide and lenalidomide in multiple myeloma","volume":"12","author":"Moehler","year":"2012","journal-title":"Curr. Cancer Drug Targets"},{"issue":"2","key":"10.1016\/j.biopha.2024.117066_bib17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1590\/S0100-879X2007000200011","article-title":"Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type II reaction in leprosy","volume":"40","author":"Sales","year":"2007","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"3","key":"10.1016\/j.biopha.2024.117066_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.47276\/lr.78.3.197","article-title":"The role of thalidomide in the management of erythema nodosum leprosum","volume":"78","author":"Walker","year":"2007","journal-title":"Lepr. Rev."},{"issue":"18","key":"10.1016\/j.biopha.2024.117066_bib19","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2303706","article-title":"Thalidomide for recurrent bleeding due to small-intestinal angiodysplasia","volume":"389","author":"Chen","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"7-8","key":"10.1016\/j.biopha.2024.117066_bib20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1159\/000506263","article-title":"Impact of routine laboratory parameters in patients undergoing radical cystectomy for urothelial carcinoma of the bladder: a long-term follow-up","volume":"104","author":"Tamalunas","year":"2020","journal-title":"Urol. Int."},{"issue":"11-12","key":"10.1016\/j.biopha.2024.117066_bib21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1159\/000510137","article-title":"Is it safe to offer radical cystectomy to patients above 85 years of age? a long-term follow-up in a single-center institution","volume":"104","author":"Tamalunas","year":"2020","journal-title":"Urol. Int"},{"key":"10.1016\/j.biopha.2024.117066_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.884057","article-title":"Inhibition of human prostate and bladder smooth muscle contraction, vasoconstriction of porcine renal and coronary arteries, and growth-related functions of prostate stromal cells by presumed small molecule galphaq\/11 inhibitor, YM-254890","volume":"13","author":"Tamalunas","year":"2022","journal-title":"Front Physiol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117066_bib23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00210-019-01727-x","article-title":"Normalization of organ bath contraction data for tissue specimen size: does one approach fit all?","volume":"393","author":"Erdogan","year":"2020","journal-title":"Naunyn Schmiede Arch. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2024.117066_bib24","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1084\/jem.103.5.653","article-title":"Action of x-rays on mammalian cells","volume":"103","author":"Puck","year":"1956","journal-title":"J. Exp. Med"},{"issue":"49","key":"10.1016\/j.biopha.2024.117066_bib25","doi-asserted-by":"crossref","DOI":"10.3791\/2573","article-title":"Clonogenic assay: adherent cells","author":"Rafehi","year":"2011","journal-title":"J. Vis. Exp."},{"issue":"23","key":"10.1016\/j.biopha.2024.117066_bib26","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1093\/bioinformatics\/btu575","article-title":"Cell population identification using fluorescence-minus-one controls with a one-class classifying algorithm","volume":"30","author":"Feher","year":"2014","journal-title":"Bioinformatics"},{"issue":"7","key":"10.1016\/j.biopha.2024.117066_bib27","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202400362R","article-title":"Isoform-independent promotion of contractility and proliferation, and suppression of survival by with no lysine\/K kinases in prostate stromal cells","volume":"38","author":"Liu","year":"2024","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2024.117066_bib28","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.121.001029","article-title":"Inhibition of full smooth muscle contraction in isolated human detrusor tissues by mirabegron is limited to off-target inhibition of neurogenic contractions","author":"Huang","year":"2022","journal-title":"J. Pharm. Exp. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.117066_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/mol.119.118927","article-title":"New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology","volume":"97","author":"Michel","year":"2020","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2024.117066_bib30","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bph.14153","article-title":"Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers","volume":"175","author":"Curtis","year":"2018","journal-title":"Br. J. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2024.117066_bib31","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nm.4128","article-title":"Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity","volume":"22","author":"Eichner","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2024.117066_bib32","first-page":"S27","article-title":"THE CONCISE GUIDE TO PHARMACOLOGY 2021\/22: G protein-coupled receptors","volume":"178 Suppl 1","author":"Alexander","year":"2021","journal-title":"Br. J. Pharm."},{"issue":"12","key":"10.1016\/j.biopha.2024.117066_bib33","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1021\/jm9705115","article-title":"6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors","volume":"41","author":"Pei","year":"1998","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.biopha.2024.117066_bib34","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/nau.22467","article-title":"Prostatic alpha1-adrenoceptors: new concepts of function, regulation, and intracellular signaling","volume":"33","author":"Hennenberg","year":"2014","journal-title":"Neurourol. Urodyn."},{"issue":"4","key":"10.1016\/j.biopha.2024.117066_bib35","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/JU.0000000000002183","article-title":"Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-initial work-up and medical management","volume":"206","author":"Lerner","year":"2021","journal-title":"J. Urol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117066_bib36","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.eururo.2006.02.018","article-title":"A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder","volume":"49","author":"Chapple","year":"2006","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117066_bib37","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1358\/dot.2004.40.3.820083","article-title":"The promise of thalidomide: evolving indications","volume":"40","author":"Joglekar","year":"2004","journal-title":"Drugs Today (Barc. )"},{"issue":"4","key":"10.1016\/j.biopha.2024.117066_bib38","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/bju.13412","article-title":"Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer","volume":"118","author":"Madan","year":"2016","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.biopha.2024.117066_bib39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0149-2918(00)88289-2","article-title":"S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide","volume":"21","author":"Zeldis","year":"1999","journal-title":"Clin. Ther."},{"key":"10.1016\/j.biopha.2024.117066_bib40","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/978-3-642-16499-6_16","article-title":"Muscarinic acetylcholine receptors in the urinary tract","volume":"202","author":"Andersson","year":"2011","journal-title":"Handb. Exp. Pharm."},{"key":"10.1016\/j.biopha.2024.117066_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.884057","article-title":"Inhibition of human prostate and bladder smooth muscle contraction, vasoconstriction of porcine renal and coronary arteries, and growth-related functions of prostate stromal cells by presumed small molecule G\u03b1q\/11 inhibitor, YM-254890","volume":"13","author":"Tamalunas","year":"2022","journal-title":"Front Physiol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117066_bib42","first-page":"194","article-title":"Management of thalidomide toxicity","volume":"1","author":"Ghobrial","year":"2003","journal-title":"J. Support Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117066_bib43","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1582-4934.2002.tb00184.x","article-title":"Thalidomide as an anti-cancer agent","volume":"6","author":"Kumar","year":"2002","journal-title":"J. Cell Mol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2024.117066_bib44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1586\/14737140.1.1.20","article-title":"Thalidomide in the treatment of multiple myeloma","volume":"1","author":"Rajkumar","year":"2001","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"1-3","key":"10.1016\/j.biopha.2024.117066_bib45","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejphar.2010.06.035","article-title":"Actions of thalidomide in producing vascular relaxations","volume":"644","author":"Seto","year":"2010","journal-title":"Eur. J. Pharm."},{"issue":"Suppl 3","key":"10.1016\/j.biopha.2024.117066_bib46","first-page":"S65","article-title":"Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer","volume":"5","author":"Leonard","year":"2003","journal-title":"Rev. Urol."},{"issue":"8","key":"10.1016\/j.biopha.2024.117066_bib47","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1097\/ICO.0b013e318292a79d","article-title":"The inhibitory effect of thalidomide analogue on corneal neovascularization in rabbits","volume":"32","author":"Lee","year":"2013","journal-title":"Cornea"},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2024.117066_bib48","first-page":"32","article-title":"Animal models of bladder outlet obstruction and molecular insights into the basis for the development of bladder dysfunction","volume":"32","author":"Buttyan","year":"1997","journal-title":"Eur. Urol."},{"issue":"6","key":"10.1016\/j.biopha.2024.117066_bib49","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.urology.2005.06.124","article-title":"Transforming growth factor-beta1-induced hypertrophy and matrix expression in human bladder smooth muscle cells","volume":"66","author":"Howard","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.biopha.2024.117066_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.630228","article-title":"Fibroblast growth factor 2 promotes bladder hypertrophy caused by partial bladder outlet obstruction","volume":"9","author":"Gao","year":"2021","journal-title":"Front Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117066_bib51","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1357-2725(99)00133-8","article-title":"Fibroblast growth factor-2","volume":"32","author":"Okada-Ban","year":"2000","journal-title":"Int J. Biochem Cell Biol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117066_bib52","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1267\/ahc.10030","article-title":"Thalidomide prevents the progression of peritoneal fibrosis in mice","volume":"44","author":"Arai","year":"2011","journal-title":"Acta Histochem Cytochem"},{"issue":"6","key":"10.1016\/j.biopha.2024.117066_bib53","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3349\/ymj.2015.56.6.1572","article-title":"Thalidomide accelerates the degradation of extracellular matrix in rat hepatic cirrhosis via down-regulation of transforming growth factor-beta1.","volume":"56","author":"Lv","year":"2015","journal-title":"Yonsei Med. J."},{"issue":"3","key":"10.1016\/j.biopha.2024.117066_bib54","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3892\/etm.2013.1457","article-title":"Function of the transforming growth factor-beta1\/c-Jun N-terminal kinase signaling pathway in the action of thalidomide on a rat model of pulmonary fibrosis.","volume":"7","author":"Liu","year":"2014","journal-title":"Exp. Ther. Med."},{"issue":"10","key":"10.1016\/j.biopha.2024.117066_bib55","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrurol.2016.168","article-title":"Inflammatory mediators in the development and progression of benign prostatic hyperplasia","volume":"13","author":"De Nunzio","year":"2016","journal-title":"Nat. Rev. Urol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117066_bib56","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrurol.2010.207","article-title":"Estrogen and androgen signaling in the pathogenesis of BPH","volume":"8","author":"Ho","year":"2011","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.biopha.2024.117066_bib57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lfs.2018.03.041","article-title":"Urinary bladder organ hypertrophy is partially regulated by Akt1-mediated protein synthesis pathway","volume":"201","author":"Qiao","year":"2018","journal-title":"Life Sci."},{"issue":"9423","key":"10.1016\/j.biopha.2024.117066_bib58","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biopha.2024.117066_bib59","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jcph.1506","article-title":"Population pharmacokinetic model to assess the impact of disease state on thalidomide pharmacokinetics","volume":"60","author":"Gaudy","year":"2020","journal-title":"J. Clin. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2024.117066_bib60","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00204-020-02669-7","article-title":"In vitro prediction of organ toxicity: the challenges of scaling and secondary mechanisms of toxicity","volume":"94","author":"Hengstler","year":"2020","journal-title":"Arch. Toxicol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117066_bib61","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s10637-010-9576-2","article-title":"In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines","volume":"30","author":"Schmidt-Hieber","year":"2012","journal-title":"Invest N. Drugs"},{"issue":"12","key":"10.1016\/j.biopha.2024.117066_bib62","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1177\/0091270007309563","article-title":"Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis","volume":"47","author":"Chen","year":"2007","journal-title":"J. Clin. Pharm."},{"issue":"17","key":"10.1016\/j.biopha.2024.117066_bib63","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2010-04-279893","article-title":"Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma","volume":"116","author":"Gorgun","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2024.117066_bib64","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s10637-022-01320-9","article-title":"Pharmacokinetics and bioequivalence of two pomalidomide capsules in healthy chinese subjects under fasting and fed conditions","volume":"41","author":"Liu","year":"2023","journal-title":"Invest N. Drugs"},{"issue":"10","key":"10.1016\/j.biopha.2024.117066_bib65","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1080\/00498254.2016.1247218","article-title":"Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice","volume":"47","author":"Shimizu","year":"2017","journal-title":"Xenobiotica"},{"issue":"10","key":"10.1016\/j.biopha.2024.117066_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21101332","article-title":"Inhibition of uterine contractility by thalidomide analogs via phosphodiesterase-4 inhibition and calcium entry blockade","volume":"21","author":"Fernandez-Martinez","year":"2016","journal-title":"Molecules"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224009508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224009508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:35:43Z","timestamp":1782174943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224009508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":66,"alternative-id":["S0753332224009508"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117066","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulatory imide drugs inhibit human detrusor smooth muscle contraction and growth of human detrusor smooth muscle cells, and exhibit vaso-regulatory functions","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117066"}}